Sponsored Webinar: How to tailor mealtime insulin to individual needs
PP-UR-GB-0429 December 2022
____________________________________________________________________________________________________________________________________________________________________
Please click here for Lyumjev®▼ (insulin lispro) Prescribing Information
Please click here for Humalog® (insulin lispro) Prescribing Information
Intended for Healthcare Professionals in Great Britain.
Lilly have sponsored the content of this meeting in partnership with ABCD. The speaker has been selected briefed and paid honorarium by Lilly. Lilly products will be discussed.
Lyumjev is indicated for the treatment of diabetes mellitus in adults only. Lyumjev is not indicated for use in children. Lyumjev is not available in Ireland.
Humalog (insulin lispro) indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus
How to tailor mealtime insulin to individual needs
Thursday 9th February 2023, 7:00pm - 8:00pm
Please join our speakers:
Dr Emma Wilmot
Consultant Diabetologist, University Hospitals of Derby and Burton NHS Foundation Trust. Founder of the ABCD Diabetes Technology Network UK
Dr Hood Thabit
Consultant diabetologist and senior lecturer at Manchester University Hospital Foundation Trust. His clinical practice is focused on type 1 diabetes, glucose sensing, automated insulin delivery systems, transition, and young adults
Meeting objectives:
- The challenge of post prandial hyperglcaemia
- The case for pump therapy vs MDI; Lyumjev®▼(insulin lispro) efficacy and safety in pumps
- Case Study Review
This presentation will include a 20 minute Q&A session
Lilly have sponsored the content of this meeting in partnership with ABCD. The speakers have been selected, briefed and paid honorarium by Lilly. Lilly products will be discussed at this meeting
Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.
Lilly have been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide solutions – from medicine to support programmes and more – we strive to make life better for all those affected by diabetes around the world.
To view Lilly privacy statement please click here: Privacy Policy
Lilly and Lyumjev® and Humalog® are registered trademarks of Eli Lilly and Company
© 2022 Eli Lilly and Company. All rights reserved
PP-UR-GB-0429 December 2022
ABCD Webinar Series
